The US Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a registration Phase III trial of iSCIB1+ Immunobody in advanced melanoma.  The application, submitted by biotechnology company Scancell Holdings, has been cleared with progression free survival as the agreed surrogate endpoint.  Scancell has completed the 140-patient SCOPE Phase II, open-label, multi-centre study evaluating ImmunoBody immunotherapies (SCIB1 […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!